MedPath

Benefit of oocyte activation with GM508 CultActive in an IVF/ICSI therapy with different clinical pictures of sub- or infertility. A prospective – randomized pilot study.

Not Applicable
Conditions
Patients with male sub- or infertility including oligoasthenoteratozoospermia of different grades as well as (non-)obstructive azoospermia.Couples with reduced fertilization rate of unclear aetiology in an ICSI cycle but potentially normal sperm parameters. Couples with reduced embryonal cleavage rate or reduced blastocyst rate in (an) previous ICSI cycle(s).
N46
N97.4
Male infertility
Female infertility associated with male factors
Registration Number
DRKS00010456
Lead Sponsor
IVF Zentren Prof. Zech
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
532
Inclusion Criteria

All IVF couples with indications for artificial oocyte activation that have signed an informed consent before therapy.
Indications are:
• Male sub- or infertility including oligoasthenoteratozoospermia of different grades and obstructive and non-obstructive azoospermia including cycles with fertilization after testicular sperm extraction (TESE)
• Couples with reduced fertilization rate after ICSI, but potentially normal spermiocytogram, as well as patients with observed reduced embryonic cleavage rate or reduced blastocyst rate after ICSI.

Exclusion Criteria

Less than 2 mature (MII) oocytes after retrieval
• female age =44 Years (no age restrictions for males )
• known chromosomal abberations of one or both partners
• egg donnation patients
• Patients with total globozoospermia (therefore oocyte activation is obligate)

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Fertilization rate; blastocyst rate in both arms; pregnancy rate: number of positive hCG tests/ number of transfers approximately 2 weeks after embryo transfer.<br>Clinical pregnancy rate: verified heart beats /number of transfers approximately 8-12 weeks after embryo transfer.<br>Miscarriage rate: number of miscarriages after confirmed embryonal heart beat<br>Live Birth rate: number of live births.<br><br>Transfer is performed by using the morphological best embryo according to the stadardized criteria of Gardner et al., 2000. In case of equal embryo quality in both arms, the embryo selection is randomized.<br>An assignment of the embryos to control and intervention arm is given by Software and CRF.<br>In the case of DET, wherein both of embryos are taken from different arms , the resulting outcome parameters for pregnancy and birth are excluded from the study evaluation.
Secondary Outcome Measures
NameTimeMethod
Elucidation of a putative Impact of artificial oocyte activation (by GM508) on the post- or neonatal outcome by questionnaire survey after delivery
© Copyright 2025. All Rights Reserved by MedPath